The strong beat on EPS and record revenue, combined with reaffirmed guidance, supports a bullish near-term outlook. Monitor the Q3 2026 10-Q for continued Wound Care growth trajectory and any update on the GE Healthcare contract's full-year impact, as Device Solutions remains a drag on headline growth.
Price Chart
Executive Summary
InfuSystem reported Q2 2026 net revenue of $36.9M (+2.6% YoY) and GAAP diluted EPS of $0.15, beating the $0.10 consensus by 50%. Patient Services revenue grew 15% YoY, driven by a 154% surge in Wound Care, while Device Solutions declined 16% due to the previously disclosed GE Healthcare contract restructuring. The company reaffirmed full-year 2026 guidance for 6-8% pro-forma revenue growth and mid-to-low 20% Adjusted EBITDA margins, signaling continued operational momentum despite the structural headwind in Device Solutions.
Key Financial Metrics
Key Facts
- Q2 2026 net revenue of $36.9M, up 2.6% YoY, a record for the company.
- GAAP diluted EPS of $0.15 beat the $0.10 consensus estimate by 50%.
- Patient Services revenue grew 15% YoY to $24.8M, with Wound Care surging 154% and Oncology surpassing $20M for the first time.
- Device Solutions revenue fell 16% YoY to $12.1M due to the GE Healthcare contract restructuring.
- Adjusted EBITDA was $8.6M, up 7.6% YoY, with margin expanding 110 bps to 23.4%.
- Full-year 2026 guidance reaffirmed: pro-forma revenue growth of 6-8% and Adjusted EBITDA margin in the mid-to-low 20% range.
- The company repurchased $3.5M in stock during the quarter and had $55.2M in available liquidity as of June 30, 2026.
Financial Impact
EPS beat of $0.05 (50% vs consensus) on revenue $0.5M above consensus; Adjusted EBITDA up 7.6% YoY to $8.6M
Risk Factors
- Device Solutions revenue continues to decline (down 16% YoY) due to the GE Healthcare contract restructuring, which may persist.
- Operating cash flow for the first half of 2026 was $7.7M, down 12% YoY, driven by higher working capital needs.
- Net debt increased to $19.5M from $16.4M at year-end 2025, though the Adjusted EBITDA-to-net-debt ratio improved to 0.61x.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-052112 |
| Document: infu-20260804.htm | 0001628280-26-052112 |
| Document: 0001628280-26-052112-index-headers.html | 0001628280-26-052112 |
| Document: 0001628280-26-052112-index.html | 0001628280-26-052112 |
| Document: 0001628280-26-052112.txt | 0001628280-26-052112 |
| 8-K Data (Synthetic) | 0001628280-26-052112 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $12.32 $12.46 | ▲ +1.14% | ▲ +1.24% | $13.81 (+12.09%) |
Aug 4, 2026 11w ago | 8-K | $12.32 $12.46 | ▲ +1.14% | ▲ +1.24% | $13.81 (+12.09%) |
Jul 28, 2026 12w ago | 8-K | $9.92 $9.22 | ▼ −7.06% | ▼ −9.33% | $13.81 (+39.21%) |
May 18, 2026 23w ago | 8-K | $9.67 $9.45 | ▼ −2.28% | ▼ −4.52% | $13.81 (+42.81%) |
May 14, 2026 23w ago | 8-K | $8.61 $9.94 | ▲ +15.45% | ▲ +16.16% | $13.81 (+60.39%) |
May 12, 2026 23w ago | 8-K | $8.21 $9.67 | ▲ +17.78% | ▲ +18.94% | $13.81 (+68.21%) |
May 8, 2026 24w ago | Insider Cluster | $8.41 $8.61 | ▲ +2.38% | ▲ +0.91% | $13.81 (+64.21%) |
May 8, 2026 24w ago | Insider Cluster | $8.41 $8.61 | ▲ +2.38% | ▲ +0.91% | $13.81 (+64.21%) |
May 7, 2026 24w ago | 8-K | $8.97 $8.21 | ▼ −8.47% | ▼ −9.98% | $13.81 (+53.96%) |
Apr 30, 2026 25w ago | 8-K | $10.13 $8.97 | ▼ −11.45% | ▼ −13.18% | $13.81 (+36.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers